Literature DB >> 20200614

Recurrent and founder mutations in the Netherlands: Extensive clinical variability in Marfan syndrome patients with a single novel recurrent fibrillin-1 missense mutation.

J J J Aalberts1, A G Schuurman, G Pals, B J C Hamel, G Bosman, Y Hilhorst-Hofstee, D Q C M Barge-Schaapveld, B J M Mulder, M P van den Berg, J P van Tintelen.   

Abstract

Background/Methods. Marfan syndrome (MFS) is a heritable connective tissue disorder usually caused by a mutation in the fibrillin 1 (FBN1) gene. Typical characteristics of MFS that have been described include dolichostenomelia, ectopia lentis and aortic root dilatation. However, there is great clinical variability in the expression of the syndrome's manifestations, both between and within families. Here we discuss the clinical variability of MFS by describing a large fourgeneration Dutch family with MFS.Results. Nineteen individuals of one family with a single missense FBN1 mutation (c.7916A>G) were identified. The same mutation was found in one unrelated person. Clinical variability was extensive and not all mutation carriers fulfilled the diagnostic criteria for MFS. Some patients only expressed mild skeletal abnormalities, whereas aortic root dilation was present in eight patients, an acute type A aortic dissection was recorded in two other patients, and a mitral valve prolapse was present in eight patients. In some patients cardiac features were not present on initial screening, but did however develop over time.Conclusion. MFS is a clinically highly variable syndrome, which means a meticulous evaluation of suspected cases is crucial. Mutation carriers should be re-evaluated regularly as cardiovascular symptoms may develop over time. (Neth Heart J 2010;18:85-9.).

Entities:  

Keywords:  Marfan Syndrome/genetics; Microfilament Proteins; Missense; Mutation; Netherlands

Year:  2010        PMID: 20200614      PMCID: PMC2828568          DOI: 10.1007/BF03091743

Source DB:  PubMed          Journal:  Neth Heart J        ISSN: 1568-5888            Impact factor:   2.380


  22 in total

1.  Phenotypic variability of cardiovascular manifestations in Marfan Syndrome. Possible role of hyperhomocysteinemia and C677T MTHFR gene polymorphism.

Authors:  Betti Giusti; Maria Cristina Porciani; Tamara Brunelli; Lucia Evangelisti; Sandra Fedi; Gian Franco Gensini; Rosanna Abbate; Guido Sani; Magdi Yacoub; Guglielmina Pepe
Journal:  Eur Heart J       Date:  2003-11       Impact factor: 29.983

2.  Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene.

Authors:  H C Dietz; G R Cutting; R E Pyeritz; C L Maslen; L Y Sakai; G M Corson; E G Puffenberger; A Hamosh; E J Nanthakumar; S M Curristin
Journal:  Nature       Date:  1991-07-25       Impact factor: 49.962

Review 3.  Making sense of latent TGFbeta activation.

Authors:  Justin P Annes; John S Munger; Daniel B Rifkin
Journal:  J Cell Sci       Date:  2003-01-15       Impact factor: 5.285

Review 4.  The molecular genetics of Marfan syndrome and related disorders.

Authors:  P N Robinson; E Arteaga-Solis; C Baldock; G Collod-Béroud; P Booms; A De Paepe; H C Dietz; G Guo; P A Handford; D P Judge; C M Kielty; B Loeys; D M Milewicz; A Ney; F Ramirez; D P Reinhardt; K Tiedemann; P Whiteman; M Godfrey
Journal:  J Med Genet       Date:  2006-03-29       Impact factor: 6.318

5.  Recurrent and founder mutations in the Netherlands: Extensive clinical variability in Marfan syndrome patients with a single novel recurrent fibrillin-1 missense mutation.

Authors:  J J J Aalberts; A G Schuurman; G Pals; B J C Hamel; G Bosman; Y Hilhorst-Hofstee; D Q C M Barge-Schaapveld; B J M Mulder; M P van den Berg; J P van Tintelen
Journal:  Neth Heart J       Date:  2010-02       Impact factor: 2.380

6.  Prevalence data on all Ghent features in a cross-sectional study of 87 adults with proven Marfan syndrome.

Authors:  Svend Rand-Hendriksen; Rigmor Lundby; Lena Tjeldhorn; Kai Andersen; Jon Offstad; Svein Ove Semb; Hans-Jørgen Smith; Benedicte Paus; Odd Geiran
Journal:  Eur J Hum Genet       Date:  2009-03-18       Impact factor: 4.246

Review 7.  Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database.

Authors:  Gwenaëlle Collod-Béroud; Saga Le Bourdelles; Lesley Ades; Leena Ala-Kokko; Patrick Booms; Maureen Boxer; Anne Child; Paolo Comeglio; Anne De Paepe; James C Hyland; Katerine Holman; Ilkka Kaitila; Bart Loeys; Gabor Matyas; Lieve Nuytinck; Leena Peltonen; Terhi Rantamaki; Peter Robinson; Beat Steinmann; Claudine Junien; Christophe Béroud; Catherine Boileau
Journal:  Hum Mutat       Date:  2003-09       Impact factor: 4.878

8.  Allelic variation in normal human FBN1 expression in a family with Marfan syndrome: a potential modifier of phenotype?

Authors:  Sarah Hutchinson; Andre Furger; Dorothy Halliday; Daniel P Judge; Andrew Jefferson; Harry C Dietz; Helen Firth; Penny A Handford
Journal:  Hum Mol Genet       Date:  2003-07-22       Impact factor: 6.150

9.  Life expectancy in British Marfan syndrome populations.

Authors:  J R Gray; A B Bridges; R R West; L McLeish; A G Stuart; J C Dean; M E Porteous; M Boxer; S J Davies
Journal:  Clin Genet       Date:  1998-08       Impact factor: 4.438

10.  Clinical and molecular study of 320 children with Marfan syndrome and related type I fibrillinopathies in a series of 1009 probands with pathogenic FBN1 mutations.

Authors:  Laurence Faivre; Alice Masurel-Paulet; Gwenaëlle Collod-Béroud; Bert L Callewaert; Anne H Child; Chantal Stheneur; Christine Binquet; Elodie Gautier; Bertrand Chevallier; Frédéric Huet; Bart L Loeys; Eloisa Arbustini; Karin Mayer; Mine Arslan-Kirchner; Anatoli Kiotsekoglou; Paolo Comeglio; Maurizia Grasso; Dorothy J Halliday; Christophe Béroud; Claire Bonithon-Kopp; Mireille Claustres; Peter N Robinson; Lesley Adès; Julie De Backer; Paul Coucke; Uta Francke; Anne De Paepe; Catherine Boileau; Guillaume Jondeau
Journal:  Pediatrics       Date:  2009-01       Impact factor: 7.124

View more
  5 in total

Review 1.  Mitral valve disease in Marfan syndrome and related disorders.

Authors:  Daniel P Judge; Rosanne Rouf; Jennifer Habashi; Harry C Dietz
Journal:  J Cardiovasc Transl Res       Date:  2011-08-25       Impact factor: 4.132

2.  Recurrent and founder mutations in the Netherlands: Extensive clinical variability in Marfan syndrome patients with a single novel recurrent fibrillin-1 missense mutation.

Authors:  J J J Aalberts; A G Schuurman; G Pals; B J C Hamel; G Bosman; Y Hilhorst-Hofstee; D Q C M Barge-Schaapveld; B J M Mulder; M P van den Berg; J P van Tintelen
Journal:  Neth Heart J       Date:  2010-02       Impact factor: 2.380

3.  The revised role of TGF-β in aortic aneurysms in Marfan syndrome.

Authors:  R Franken; T Radonic; A W den Hartog; M Groenink; G Pals; M van Eijk; R Lutter; B J M Mulder; A H Zwinderman; V de Waard
Journal:  Neth Heart J       Date:  2015-02       Impact factor: 2.380

4.  Multi-scale biomechanical remodeling in aging and genetic mutant murine mitral valve leaflets: insights into Marfan syndrome.

Authors:  Russell A Gould; Ravi Sinha; Hamza Aziz; Rosanne Rouf; Harry C Dietz; Daniel P Judge; Jonathan Butcher
Journal:  PLoS One       Date:  2012-09-11       Impact factor: 3.240

5.  Next-generation sequencing for diagnosis of thoracic aortic aneurysms and dissections: diagnostic yield, novel mutations and genotype phenotype correlations.

Authors:  J K Poninska; Z T Bilinska; M Franaszczyk; E Michalak; M Rydzanicz; E Szpakowski; A Pollak; B Milanowska; G Truszkowska; P Chmielewski; A Sioma; H Janaszek-Sitkowska; A Klisiewicz; I Michalowska; M Makowiecka-Ciesla; P Kolsut; P Stawinski; B Foss-Nieradko; M Szperl; J Grzybowski; P Hoffman; A Januszewicz; M Kusmierczyk; R Ploski
Journal:  J Transl Med       Date:  2016-05-04       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.